Taken together, these results suggest that the SARS‐Cov‐2 spike protein, a target of the COVID‐19 vaccine, disrupts insulin signaling only in patients with T2D, whereas metformin attenuates the COVID‐19 vaccine booster‐induced changes in insulin sensitivity. Here, PROS1 is linked to type 2 diabetes mellitus.